12 Amendments of Soledad CABEZÓN RUIZ related to 2017/2576(RSP)
Amendment 4 #
Citation 11 a (new)
- having regard to the first Global Health Sector Strategy on viral hepatitis 2016-2021 which, adopted by the World Health Assembly in May 2016, emphasises the crucial role of universal health coverage and whose goals are aligned with the Sustainable Development Goals, namely to reduce new cases by 90%, and mortality by 65%, by 2030, and ultimately to eliminate viral hepatitis as a public health threat,
Amendment 12 #
Citation 12 a (new)
- having regard to the European Parliament report of 2 March 2017 entitled 'Options for improving access to medicines' in which the Commission and the Member States are urged to adopt strategic plans to ensure access to life- saving medicines and to coordinate a plan to eradicate hepatitis C in the European Union by means of tools such as European joint procurement,
Amendment 26 #
Recital K a (new)
Ka. whereas there are between 130 and 150 million people in the world with chronic hepatitis C virus infection and whereas approximately 700 000 people die every year from liver diseases related to hepatitis C;
Amendment 28 #
Recital K a (new)
K a. Whereas in 2014, 35 321 cases of hepatitis C were reported from 28 EU/EEA Member States, a crude rate of 8.8 cases per 100 000 population 2a. _________________ 2a Annual Epidemiological Report - ECDC. http://ecdc.europa.eu/en/healthtopics/hep atitis_C/Documents/aer2016/AER- hepatitis-C.pdf
Amendment 31 #
Recital K b (new)
K b. Whereas between 2006 and 2014, the overall number of cases diagnosed and reported across all EU/EEA Member States increased by 28.7%, with most of this increase observed since 2010 3a. _________________ 3a Annual Epidemiological Report - ECDC. http://ecdc.europa.eu/en/healthtopics/hep atitis_C/Documents/aer2016/AER- hepatitis-C.pdf
Amendment 33 #
Recital K c (new)
K c. Whereas the interpretation of hepatitis C data across countries is hampered by differences in surveillance systems, testing practices and programmes, and difficulties in defining the cases as acute or chronic 4a. _________________ 4a Annual Epidemiological Report - ECDC. http://ecdc.europa.eu/en/healthtopics/hep atitis_C/Documents/aer2016/AER- hepatitis-C.pdf
Amendment 79 #
Paragraph 23
23. Points out that around 30% of people with chronic hepatitis C suffer from liver damage and a small number of those develop cancer, and that Hepatitis C is considered to be one ofStresses that over 90 % of patients do not have any symptoms when they contract the disease with it usually being discovered by chance during analysis or when symptoms begin to appear owing to its having caused chronic hepatitis in 55 % to 85 % of cases, and that in these cases there is a 15 % to 30 % risk of liver cirrhosis after 20 years, this being in turn the leadmaing causes of liver cancer and liver transplants in Europehepatocellular carcinoma;
Amendment 80 #
Paragraph 23 a (new)
23a. Emphasises that in 75 % of cases of hepatocellular carcinoma, the patient presents with positive HCV serology;
Amendment 81 #
Paragraph 23 b (new)
23b. Emphasises that there is no standardised protocol in the Member States for hepatitis C screening and that data on numbers of people affected may be underestimated;
Amendment 82 #
Paragraph 23 c (new)
23c. Emphasises that in April 2016 the WHO updated its Guidelines on the screening, care and treatment of persons with chronic hepatitis C infection, and that these complement existing WHO guidance on preventing the transmission of bloodborne viruses, including HVC; points out that these Guidelines provide key recommendations in these areas and discuss considerations for implementation;
Amendment 88 #
Paragraph 24 a (new)
24a. Regrets that there is no vaccine available at present for hepatitis C, rendering primary and secondary prevention crucial; emphasises, however, that the specific characteristics of hepatitis C infection and the lack of screening protocols impede testing in many cases;
Amendment 90 #
Paragraph 24 b (new)
24b. Calls on the Commission, under the direction of the ECDC, to launch a multidisciplinary plan, in coordination with the Member States, to eradicate hepatitis C in the EU by 2030 and which will standardise screening, testing and treatment protocols;